Sponsors (15)
Introduced April 8, 2025 by Richard Blumenthal · Last progress April 8, 2025
The bill directs targeted federal funding and programs to accelerate brain tumor research, expand trial access, and improve survivorship care—trading increased taxpayer spending and implementation, privacy, and resource‑diversion risks for potential patient benefits and strengthened research and clinical infrastructure.
Patients with brain tumors (adult and pediatric) could gain earlier access to new and more effective therapies because the bill creates targeted NIH funding and programs to support glioblastoma and brain‑tumor immunotherapy research, preclinical work, and early‑phase trials.
Researchers and institutions will have faster, more efficient access to NIH-funded brain tumor biospecimen information and dedicated research dollars, enabling multi‑institutional studies and reducing duplication of specimen collection.
Patients and caregivers will get improved information and supports to find and enroll in cancer clinical trials, and clinicians will receive targeted education—likely increasing trial awareness, participation, and referrals (including in underserved areas).
Taxpayers face increased federal spending (notably ~$60M/year for the immunotherapy program plus additional smaller authorizations) that could add to deficits or force tradeoffs with other priorities.
Targeted funding and program requirements risk diverting NIH and other federal resources away from other diseases or research areas, potentially affecting broader scientific priorities.
Broader trial inclusion guidance, stronger outreach, and publicity about trials could raise patient expectations and—if safeguards are inadequate—expose fragile patients to risks from interventions not tailored to them.
Based on analysis of 12 sections of legislative text.
Strengthens NIH brain tumor research and care: public biospecimen listings, new glioblastoma and cellular immunotherapy programs, survivorship pilots, outreach campaigns, and FDA guidance.
Creates new federal actions to accelerate research, improve clinical trials access, and strengthen care for people with brain tumors. It requires NIH to publish a searchable public catalog of NIH-funded brain tumor biospecimen collections, funds new multi‑institution research programs focused on glioblastoma and cellular immunotherapies, supports pilot grants for survivorship care models, and directs an HHS national outreach campaign plus FDA guidance to reduce inappropriate exclusion of brain tumor patients from clinical trials. Sets reporting deadlines for existing and new NIH-funded biospecimen collections, authorizes multi-year funding for research networks and programs, and includes oversight tools for NIH and requirements for culturally competent public education and demonstration projects to improve trial awareness and biomarker testing.